Biologicale News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Japan's Takeda Pharmaceutical will scale up production of its dengue vaccine Qdenga through a partnership with Indian vaccines maker Biological E., the companies said on Tuesday. These doses will be available for governments in endemic countries by 2030 as part of their national immunization programmes. Biological E. will ramp up to a manufacturing capacity of 50 million doses a year, accelerating Takeda's efforts to produce 100 million doses per year within a decade, the companies said.

This means that those above the age of 18 who have been fully vaccinated with Covishield or Covaxin vaccines can take Biological E Limited’s Corbevax as their booster or third shot.

Corbevax is the first vaccine to be developed locally against COVID-19 containing a Receptor-Binding Domain (RBD) protein sub-unit, , Corbevax Vaccine, Biological E., vaccination drive, national institutes of health, narendra modi

Cadila Healthcare stock fell to its 52-week low today after the Drugs Controller General of India (DCGI) cleared the COVID-19 vaccine of competitor Biological E against the company's own vaccine ZyCoV-D.

DENVER -- Denver’s top public safety leader says he is prepared to discipline police...